Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jul;24(7):954-960.
doi: 10.1038/s41591-018-0024-8. Epub 2018 May 28.

Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase

Dietrich A Ruess  1   2 , Guus J Heynen  3 , Katrin J Ciecielski  1 , Jiaoyu Ai  1 , Alexandra Berninger  1 , Derya Kabacaoglu  1 , Kivanc Görgülü  1 , Zahra Dantes  1 , Sonja M Wörmann  1 , Kalliope N Diakopoulos  1 , Angeliki F Karpathaki  1 , Marlena Kowalska  1 , Ezgi Kaya-Aksoy  1 , Liang Song  1 , Eveline A Zeeuw van der Laan  3 , María P López-Alberca  4 , Marc Nazaré  4 , Maximilian Reichert  1 , Dieter Saur  1 , Mert M Erkan  5 , Ulrich T Hopt  2 , Bruno Sainz Jr  6 , Walter Birchmeier  3 , Roland M Schmid  1 , Marina Lesina  1 , Hana Algül  7
Affiliations
Free article

Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase

Dietrich A Ruess et al. Nat Med. 2018 Jul.
Free article

Abstract

The ubiquitously expressed non-receptor protein tyrosine phosphatase SHP2, encoded by PTPN11, is involved in signal transduction downstream of multiple growth factor, cytokine and integrin receptors1. Its requirement for complete RAS-MAPK activation and its role as a negative regulator of JAK-STAT signaling have established SHP2 as an essential player in oncogenic signaling pathways1-7. Recently, a novel potent allosteric SHP2 inhibitor was presented as a viable therapeutic option for receptor tyrosine kinase-driven cancers, but was shown to be ineffective in KRAS-mutant tumor cell lines in vitro8. Here, we report a central and indispensable role for SHP2 in oncogenic KRAS-driven tumors. Genetic deletion of Ptpn11 profoundly inhibited tumor development in mutant KRAS-driven murine models of pancreatic ductal adenocarcinoma and non-small-cell lung cancer. We provide evidence for a critical dependence of mutant KRAS on SHP2 during carcinogenesis. Deletion or inhibition of SHP2 in established tumors delayed tumor progression but was not sufficient to achieve tumor regression. However, SHP2 was necessary for resistance mechanisms upon blockade of MEK. Synergy was observed when both SHP2 and MEK were targeted, resulting in sustained tumor growth control in murine and human patient-derived organoids and xenograft models of pancreatic ductal adenocarcinoma and non-small-cell lung cancer. Our data indicate the clinical utility of dual SHP2/MEK inhibition as a targeted therapy approach for KRAS-mutant cancers.

PubMed Disclaimer

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

Publication types

MeSH terms

Substances

-